A randomized, double-blind trial of 2.5 mg and 5 mg vortioxetine (Lu AA21004) versus placebo for 8 weeks in adults with major depressive disorder.
about
Vortioxetine for depression in adultsVortioxetineProfile of vortioxetine in the treatment of major depressive disorder: an overview of the primary and secondary literatureTreatment-emergent sexual dysfunction in randomized trials of vortioxetine for major depressive disorder or generalized anxiety disorder: a pooled analysis.The safety and tolerability of vortioxetine: Analysis of data from randomized placebo-controlled trials and open-label extension studies.Pharmacology and clinical potential of vortioxetine in the treatment of major depressive disorder.A randomised, double-blind study in adults with major depressive disorder with an inadequate response to a single course of selective serotonin reuptake inhibitor or serotonin-noradrenaline reuptake inhibitor treatment switched to vortioxetine or agUnder the Influence: The Interplay among Industry, Publishing, and Drug Regulation.Vortioxetine: a New Treatment for Major Depressive Disorder.Safety, tolerability, and efficacy of vortioxetine (Lu AA21004) in major depressive disorder: results of an open-label, flexible-dose, 52-week extension studyThe safety and efficacy of vortioxetine for acute treatment of major depressive disorder: a systematic review and meta-analysis.Vortioxetine in the treatment of adult patients with major depressive disorder: a meta-analysis of randomized double-blind controlled trialsDepression and cerebrovascular disease: could vortioxetine represent a valid treatment option?Vortioxetine: a meta-analysis of 12 short-term, randomized, placebo-controlled clinical trials for the treatment of major depressive disorderA randomized, double-blind, duloxetine-referenced study comparing efficacy and tolerability of 2 fixed doses of vortioxetine in the acute treatment of adults with MDD.Pharmacokinetic drug interactions involving vortioxetine (Lu AA21004), a multimodal antidepressantNew generation multi-modal antidepressants: focus on vortioxetine for major depressive disorder.Efficacy and safety of vortioxetine (Lu AA21004), 15 and 20 mg/day: a randomized, double-blind, placebo-controlled, duloxetine-referenced study in the acute treatment of adult patients with major depressive disorderThe effect of vortioxetine on overall patient functioning in patients with major depressive disorder.Serotonergic modulation of glutamate neurotransmission as a strategy for treating depression and cognitive dysfunctionVortioxetine for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antidepressant - what is the number needed to treat, number needed to harm and likelihood to be helped or harmed?Vortioxetine for the treatment of depression.Pharmacokinetic evaluation of vortioxetine for the treatment of major depressive disorder.Vortioxetine: a review of its use in major depressive disorder.Vortioxetine for the treatment of major depressive disorder.A review of the clinical efficacy, safety and tolerability of the antidepressants vilazodone, levomilnacipran and vortioxetine.The efficacy of vortioxetine for the treatment of major depressive disorder.Vortioxetine : a review of efficacy, safety and tolerability with a focus on cognitive symptoms in major depressive disorder.Vortioxetine for depression in adults.Problems in the Descriptions of the Psychiatric Inclusion and Exclusion Criteria in Publications of Antidepressant Efficacy Trials: A Qualitative Review and Recommendations for Improved Clarity.Vortioxetine versus Duloxetine in the Treatment of Patients with Major Depressive Disorder: A Meta-Analysis of Randomized Controlled Trials.Efficacy, safety, and tolerability of vortioxetine for the treatment of major depressive disorder in patients aged 55 years or older.A Population Pharmacokinetic-Pharmacodynamic Meta-Analysis of Vortioxetine in Patients with Major Depressive Disorder.Meta-analysis: Risk of hyperhidrosis with second-generation antidepressants.The Black Book of Psychotropic Dosing and Monitoring.Pharmacokinetics, Safety, and Tolerability of Vortioxetine Following Single- and Multiple-Dose Administration in Healthy Japanese Adults.The impact of antidepressant treatments on family functioning in adults with major depressive disorder: a post hoc comparison of vortioxetine and agomelatine.Comment on Fu, J. and Chen, Y.: The efficacy and safety of 5 mg/d vortioxetine compared to placebo for major depressive disorder: a meta-analysis.The efficacy and safety of 5 mg/d Vortioxetine compared to placebo for major depressive disorder: A meta-analysis.Vortioxetine: first global approval.
P2860
Q24186313-C9D848D6-8AA4-4019-AFDA-A80F577E9D37Q26773284-BFE5BECE-1877-42DC-AB0C-14A07C6C4207Q26796436-AE7580DD-83EB-4FAD-AC65-99E3FC098C22Q30278078-C5258C7C-894F-41EF-96F4-B5FEB8C9360AQ31044175-D757DB3B-4E5F-4B6A-9A81-237BE1486B08Q33933912-729345D2-FEB5-4E25-B852-80A2FB18A488Q34041642-2548AD4F-8B5B-4753-BF03-D08AEA0BC18DQ34046215-5D8E38B3-D6B1-4073-9450-7F54894E37ADQ34505568-F1B16DFB-4760-4C0F-95A7-8F8D04183887Q34531545-F370F3C2-1606-4121-85DD-E38B4BDD5E75Q35154113-040940D5-7C0D-4EF8-B90A-953110AE6402Q35280477-BEA4F980-959E-4C8F-AC0D-A343BC94CF4DQ35426685-A16E3EE5-676C-4784-8994-90955010BA3CQ35536869-60ADCBFC-4486-4A8F-BBD0-EF5FDAD8CCF4Q35607556-EBB676BA-AB3D-4B5A-B83A-78A86A0CBA73Q37177088-C84D6280-98B6-46F4-8A48-DB38C839F0E9Q37601281-AC97A293-8C81-48D5-AEC8-9691E42CF24AQ37692558-69E7CF78-F756-4D36-8D6D-28331241A8CFQ37694366-F4F390FD-71BE-4EF8-9168-0AD4980EC79EQ38125568-302A42C2-255E-49A7-AE31-4DD5E11CCF31Q38156001-326E1B69-AF28-4A34-8F28-69D61BBAEEACQ38199987-755A7BBA-4F5B-41FE-8599-3B15195C5878Q38200656-8825D830-D8FF-4447-827C-3EC04439962EQ38242001-47783542-701B-465E-A98D-062B9C2DCF78Q38244159-D475583F-198A-4C3B-8CD8-738A5A5917DDQ38249999-3B787572-3FF4-4C64-B4AF-81152BB765B9Q38270790-29CEB656-1AAA-4776-BD20-1D557F80B380Q38506798-ABDC877C-CC95-42EB-9D2D-685EA258364FQ38693309-CFF50CD3-2B68-4483-A6D9-1DEAC97B1791Q38714376-A3C747FE-CB05-4BAB-B214-6680D8FAC5E1Q38805096-F7F6D55F-528A-41E5-807F-6C7D2ECEBC9AQ39169446-3CA106D2-321F-4004-B522-8E5951FF5530Q40366493-2FF12595-3D96-4B42-97C1-70C81B875E41Q46182025-E3715FC2-659E-4F9D-A8A9-5B666DF432F1Q47642128-B3FD40FA-A527-46F8-A33D-44DF1A996A41Q47760557-1F38A14B-3720-4FF8-AEDE-0063E97DD0B4Q47950300-889CF801-34CA-4E44-84AD-45F7CC08D698Q47987273-8FD5BFAE-7652-4262-A06B-09E3E5CE9DB1Q48285675-2718E29D-49BB-4B5D-822A-D71BDA30BADFQ48390325-60B9F763-F8A6-4004-84E2-8A62CB6E088B
P2860
A randomized, double-blind trial of 2.5 mg and 5 mg vortioxetine (Lu AA21004) versus placebo for 8 weeks in adults with major depressive disorder.
description
2013 nî lūn-bûn
@nan
2013 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
A randomized, double-blind tri ...... ith major depressive disorder.
@ast
A randomized, double-blind tri ...... ith major depressive disorder.
@en
A randomized, double-blind tri ...... ith major depressive disorder.
@nl
type
label
A randomized, double-blind tri ...... ith major depressive disorder.
@ast
A randomized, double-blind tri ...... ith major depressive disorder.
@en
A randomized, double-blind tri ...... ith major depressive disorder.
@nl
prefLabel
A randomized, double-blind tri ...... ith major depressive disorder.
@ast
A randomized, double-blind tri ...... ith major depressive disorder.
@en
A randomized, double-blind tri ...... ith major depressive disorder.
@nl
P2093
P1476
A randomized, double-blind tri ...... ith major depressive disorder.
@en
P2093
Atul R Mahableshwarkar
Paula L Jacobsen
Yinzhong Chen
P304
P356
10.1185/03007995.2012.761600
P407
P577
2013-01-17T00:00:00Z